KRAS-Targeted Vaccine Shows Durable Immune Responses, Survival Benefits in Pancreatic Colorectal Cancers

Elicio Therapeutics’ ELI-002 2P cancer vaccine shows promising survival benefits in pancreatic and colorectal cancer patients, enhancing immune responses.

administrator

Related Articles